Transcranial photobiomodulation for reducing symptoms of autism spectrum disorder and modulating brain electrophysiology in children aged 2–7: an open label study
Fradkin Y, Anguera JA, Simon AJ, et al.
Frontiers in Child and Adolescent Psychiatry · 2025
- Study type
- Open-label study
- Population
- Children ages 2–7 with autism
- Source access
- Open access
An uncontrolled study of 23 children with autism examined changes in clinical scores and brain electrophysiology after transcranial PBM.
What to keep in mind
This is an open-label, one-arm study, not a randomized trial. Without a concurrent control group, changes cannot confidently be attributed to PBM rather than expectations, development or other care. Reported short-term tolerability does not establish long-term safety. Read the funding and conflict-of-interest disclosures alongside the results.
Research information is not a prescription. Long-term pediatric transcranial PBM safety is not established by these studies; adult evidence is not a substitute for pediatric evidence. Use only under qualified clinical guidance, with device-specific safety review.
Read the open-access articleThe original publication opens at its journal or research repository. Full text availability depends on the source; articles have not been copied or rehosted.